MedPath

UBI PHARMA INC.

UBI PHARMA INC. logo
🇹🇼Taiwan
Ownership
Public
Established
2014-01-01
Employees
251
Market Cap
-
Website
http://www.ubi-pharma.com

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

5

FDA:5

Drug Approvals

DESMOPRESSIN ACETATE

Approval Date
Oct 16, 2023
FDA

Voriconazole

Approval Date
Mar 13, 2023
FDA

DESMOPRESSIN ACETATE

Approval Date
Sep 30, 2022
FDA

CASPOFUNGIN ACETATE

Approval Date
Oct 12, 2021
FDA

Terbutaline Sulfate

Approval Date
Feb 15, 2019
FDA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

Phase 3
Completed
Conditions
Renal Anemia
First Posted Date
2016-03-15
Last Posted Date
2023-12-06
Lead Sponsor
UBI Pharma Inc.
Target Recruit Count
269
Registration Number
NCT02708914

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.